Showing 6021-6030 of 9118 results for "".
- Alphaeon Launches PROVOQUE™ Facial Serumhttps://practicaldermatology.com/news/alphaeon-launches-provoque-facial-serum/2458567/Alphaeon Corporation has launched PROVOQUE™ Facial Serum to help address the visible signs of skin aging. PROVOQUE Facial Serum is a stem cell-conditioned media containing growth factors secreted by stem cells.
- Dove Survey: Life Without Deodorant Would Be the Pitshttps://practicaldermatology.com/news/dove-survey-life-without-deodorant-would-be-the-pits/2458566/And the winner is … deodorant. Out of all the products women use in their morning beauty routine, deodorant is what makes them feel most confident– it’s twice as significant as toothpaste, four times that of foundation, nearly six times that of mascara and ten tim
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app 
- ASDS: Skin Cancer Treatments Among Most Frequently Performed Procedures in 2015https://practicaldermatology.com/news/asds-skin-cancer-treatments-among-most-frequently-performed-procedures-in-2015/2458576/Dermatologic surgeons performed nearly 10 million medical and cosmetic procedures in 2015 – up 5 percent since 2014 and 27 percent since 2012, according to the 2015 American Society for Dermatologic Surgery (ASDS) Survey on
- Use of Personal Care Products During Pregnancy Linked to Adverse Effects in Newbornshttps://practicaldermatology.com/news/use-of-personal-care-products-during-pregnancy-linked-to-adverse-effects-in-newborns/2458575/Personal care products used during pregnancy may be linked to adverse reproductive effects in newborns, report researchers from SUNY Downstate Medical Center’s School of Public Health. The long-term consequences of this are not clear and the findings must be reproduced in larg
- Mission Pharmacal's Lycelle Head Lice Removal Kit Now Available In Pharmacieshttps://practicaldermatology.com/news/mission-pharmacals-lycelle-head-lice-removal-kit-now-available-in-pharmacies/2458578/Mission Pharmacal's former prescription Lycelle Head Lice Removal Kit will now be available without a prescription. Lycelle is a treatment for the elimination of head lice and their eggs. Lycelle uses a non-pesticidal formulation that is safe for use with children as young as two years o
- Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeanthttps://practicaldermatology.com/news/joseph-c-papa-assumes-role-of-chairman-and-chief-executive-officer-of-valeant/2458580/Joseph C. Papa has assumed the role of Chairman and Chief Executive Officer at Valeant Pharmaceuticals International, Inc. As previously announced, Joseph C. Papa succeeds J. Michael Pearson. &quo
- Lilly's Taltz Now Available for Psoriasishttps://practicaldermatology.com/news/lillys-taltz-now-available-for-psoriasis/2458581/Eli Lilly and Company's Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States. Lilly is also offering patient support programs to help ensu
- Largest Independent US Psoriasis Registry to Track Safety of Ixekizumab Biologic Treatmenthttps://practicaldermatology.com/news/largest-independent-us-psoriasis-registry-to-track-safety-of-ixekizumab-biologic-treatment/2458583/The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab, Eli Lilly and Company's biologic medication that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation